# US 2013/0280260 A1 · Osteoclastogenesis inhibitor containing anti-vdac antibody

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0280260 A1
- Document ID: US20130280260A1
- Status: Published application
- Kind: A1
- Application number: 13/824,554
- Filed: 2011-10-13
- Published: 2013-10-24
- Earliest claimed: 2010-10-13
- Assignees: Tokyo Women's Medical University
- Inventors: Shigeru Kotaka; Yuki Nanke; Toru Yago; Manabu Kawamoto; Hisashi Yamanaka
- Web page: https://patentgrep.com/patent/US20130280260A1

## CPC

- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention provides a therapeutic agent or a preventative agent containing anti-VDAC antibody for diseases in which there is increased activation of osteoclasts, such as rheumatoid arthritis, and an inhibitor of human osteoclast formation containing anti-VDAC antibody.

## Claims

### Claim at position 1

1-15. (canceled)

### Claim 16

An osteoclastogenesis inhibitor comprising an anti-VDAC antibody, or a Fab fragment or a F(ab′)2 fragment thereof.

### Claim 17 (depends on 16)

The osteoclastogenesis inhibitor according to claim 16, wherein osteoclasts are human osteoclasts.

### Claim 18 (depends on 16)

The osteoclastogenesis inhibitor according to claim 16, wherein an epitope for the anti-VDAC antibody comprises 20 or less amino acid residues.

### Claim 19 (depends on 16)

The osteoclastogenesis inhibitor according to claim 16, wherein an epitope for the anti-VDAC antibody comprises an amino acid sequence of SEQ ID NO: 1.

### Claim 20

A method for inhibiting osteoclastogenesis, comprising an administrating an anti-VDAC antibody to a patient in need thereof.

### Claim 21 (depends on 20)

The method according to claim 20, wherein an epitope for the anti-VDAC antibody comprises 20 or less amino acid residues.

### Claim 22 (depends on 20)

The method according to claim 20, wherein an epitope for the anti-VDAC antibody comprises an amino acid sequence of SEQ ID NO: 1.

### Claim 23

A pharmaceutical composition for treating or preventing a disease having an increased activation of osteoclasts, comprising an anti-VDAC antibody, or a Fab fragment or a F(ab′)2 fragment thereof.

### Claim 24 (depends on 23)

The pharmaceutical composition according to claim 23, wherein the disease having an increased activation of osteoclasts is selected from the group consisting of osteoporosis, rheumatoid arthritis, Paget's disease, and bone metastases.

### Claim 25 (depends on 23)

The pharmaceutical composition according to claim 23, wherein the osteoclasts are human osteoclasts.

### Claim 26 (depends on 23)

The pharmaceutical composition according to claim 23, wherein an epitope for the anti-VDAC antibody comprises 20 or less amino acid residues.

### Claim 27 (depends on 23)

The pharmaceutical composition according to claim 23, wherein the epitope for the anti-VDAC antibody comprises an amino acid sequence of SEQ ID NO: 1.

### Claim 28

A method for treating or preventing a disease having an increased activation of osteoclasts, comprising an administrating an anti-VDAC antibody to a patient in need thereof.

### Claim 29 (depends on 28)

The method according to claim 28, wherein an epitope for the anti-VDAC antibody comprises 20 or less amino acid residues.

### Claim 30 (depends on 28)

The method according to claim 28, wherein the epitope for the anti-VDAC antibody comprises an amino acid sequence of SEQ ID NO: 1.
